Recently, the U. S. Food and Drug Administration (FDA) added its strongest warning to the label for blood thinner drug Plavix. Plavix is Bristol Myers Squibb's ( ) lead drug. It is an antiplatelet blood thinner indicated to reduce the risk of heart attack in patients with atherosclerosis (the build up of plaque and hardening of the arteries). 
Share:  Recently, the U. S. Food and Drug Administration (FDA) added its strongest warning to the label for blood thinner drug <span class="company">Plavix</span>. <span class="company">Plavix</span> is Bristol Myers Squibb's ( ) lead drug. It is an antiplatelet blood thinner indicated to reduce the risk of heart attack in patients with atherosclerosis (the build up of plaque and hardening of the arteries). Tweet this 

Bristol Myers Squibb CEO Jim Cornelius didn't fare too badly during his last full year on the job: According to the company's preliminary proxy statement, his pay dropped a bit, to $18.2 million from $19.7 million. But it's still a lot more than he earned back in 2007. . The biggest drop for Cornelius came in his option awards, which amounted to $5.2 million for 2009, down from $7.15 million in 2008. 
Share:  <span class="company">Bristol Myers Squibb</span> CEO Jim Cornelius didn't fare too badly during his last full year on the job: According to the company's preliminary proxy statement, his pay dropped a bit, to $18.2 million from $19.7 million. But it's still a lot more than he earned back in 2007. . The biggest drop for Cornelius came in his option awards, which amounted to $5.2 million for 2009, down from $7.15 million in 2008. Tweet this 

Recently, Bristol Myers Squibb ( ) announced that it has commenced a phase IV (post marketing) study for its type II diabetes drug Onglyza (saxagliptin). Bristol Myers entered into collaboration with AstraZeneca plc ( ) in to research, develop and commercialize select candidates for type II diabetes. The post marketing study was partly designed to fulfill the requirement of the U. S. Food and Drug Administration (FDA) in addition to finding out the potential benefit of the drug beyond glucose reduction. 
Share:  Recently, <span class="company">Bristol Myers Squibb</span> ( ) announced that it has commenced a phase IV (post marketing) study for its type II diabetes drug Onglyza (saxagliptin). Bristol Myers entered into collaboration with AstraZeneca plc ( ) in to research, develop and commercialize select candidates for type II diabetes. The post marketing study was partly designed to fulfill the requirement of the U. S. Food and Drug Administration (FDA) in addition to finding out the potential benefit of the drug beyond glucose reduction. Tweet this 

Recently, Bristol Myers Squibb Co ( ) and Pfizer Inc ( ) announced that apixaban, a blood thinner being co developed by the two companies, was found to be more effective than Sanofi Aventis' ( ) Lovenox (enoxaparin) in a late stage randomized, double blind, multicenter, head to head study. The candidate was found to be statistically superior to 40 mg once daily enoxaparin in reducing blood clots in the legs or lungs (venous thromboembolism) in patients undergoing total knee replacement surgery. In the late stage study, patients were administered either 2.5 milligrams of apixaban twice a day, or a daily 40 milligram injection of enoxaparin. 
Share:  Recently, <span class="company">Bristol Myers Squibb</span> Co ( ) and Pfizer Inc ( ) announced that apixaban, a blood thinner being co developed by the two companies, was found to be more effective than Sanofi Aventis' ( ) Lovenox (enoxaparin) in a late stage randomized, double blind, multicenter, head to head study. The candidate was found to be statistically superior to 40 mg once daily enoxaparin in reducing blood clots in the legs or lungs (venous thromboembolism) in patients undergoing total knee replacement surgery. In the late stage study, patients were administered either 2.5 milligrams of apixaban twice a day, or a daily 40 milligram injection of enoxaparin. Tweet this 

Of the 22 analysts who follow the company, five recommend investors buy the stock. "The Plavix patent expiration is going to be very painful, and I think investors are underestimating this," said Vishal Manchanda of Mehta Partners LLC in New York, who has a "sell" rating on Bristol Myers, in a telephone interview. "I do expect a dip in the share price; that is almost certain." . Andreotti was long seen as a top contender for the CEO's position and his selection isn't a surprise to investors, said Les Funtleyder, a Miller Tabak & Co analyst in New York, in a telephone interview. Now, Andreotti must deliver on the company's pipeline of experimental medicines, Funtleyder said. 
Share:  Of the 22 analysts who follow the company, five recommend investors buy the stock. "The Plavix patent expiration is going to be very painful, and I think investors are underestimating this," said Vishal Manchanda of Mehta Partners LLC in New York, who has a "sell" rating on <span class="company">Bristol Myers</span>, in a telephone interview. "I do expect a dip in the share price; that is almost certain." .<span class="sent"> Andreotti was long seen as a top contender for the CEO's position and his selection isn't a surprise to investors, said <span class="analyst">Les Funtleyder</span>, a Miller Tabak & Co analyst in New York, in a telephone interview.</span> Now, Andreotti must deliver on the company's pipeline of experimental medicines, Funtleyder said. Tweet this 

Of the 22 analysts who follow the company, five recommend investors buy the stock. "The Plavix patent expiration is going to be very painful, and I think investors are underestimating this," said Vishal Manchanda of Mehta Partners LLC in New York, who has a "sell" rating on Bristol Myers, in a telephone interview. "I do expect a dip in the share price; that is almost certain." . Andreotti was long seen as a top contender for the CEO's position and his selection isn't a surprise to investors, said Les Funtleyder, a Miller Tabak & Co analyst in New York, in a telephone interview. Now, Andreotti must deliver on the company's pipeline of experimental medicines, Funtleyder said. 
Share:  Of the 22 analysts who follow the company, five recommend investors buy the stock.<span class="sent"> "The Plavix patent expiration is going to be very painful, and I think investors are underestimating this," said <span class="analyst">Vishal Manchanda</span> of Mehta Partners LLC in New York, who has a "sell" rating on <span class="company">Bristol Myers</span>, in a telephone interview.</span> "I do expect a dip in the share price; that is almost certain." . Andreotti was long seen as a top contender for the CEO's position and his selection isn't a surprise to investors, said Les Funtleyder, a Miller Tabak & Co analyst in New York, in a telephone interview. Now, Andreotti must deliver on the company's pipeline of experimental medicines, Funtleyder said. Tweet this 

Sales of the antipsychotic Abilify will start to tumble in 2014, eliminating about $3 billion in revenue by 2016. Even if all the drugs being developed at Bristol Myers make it to market as planned, sales in 2016 will fall about $3.9 billion lower than in 2011, Fernandez said. Andreotti said he plans to make more acquisitions in the near term to help address those losses, and has $10 billion in cash to do so with. "Like other drug companies, Bristol Myers may also acquire its way to its stated financial targets if needed," said Tim Anderson, an analyst with Sanford C. Bernstein & Co in New York, in a note to investors. "Although it has been steadfast in saying it would only pursue smaller deals as part of its ‘string of pearls' approach, we continue to wonder whether a larger transaction might ultimately occur." 
Share:  Sales of the antipsychotic Abilify will start to tumble in 2014, eliminating about $3 billion in revenue by 2016. Even if all the drugs being developed at <span class="company">Bristol Myers</span> make it to market as planned, sales in 2016 will fall about $3.9 billion lower than in 2011, Fernandez said. Andreotti said he plans to make more acquisitions in the near term to help address those losses, and has $10 billion in cash to do so with.<span class="sent"> "Like other drug companies, <span class="company">Bristol Myers</span> may also acquire its way to its stated financial targets if needed," said <span class="analyst">Tim Anderson</span>, an analyst with Sanford C. Bernstein & Co in New York, in a note to investors.</span> "Although it has been steadfast in saying it would only pursue smaller deals as part of its ‘string of pearls' approach, we continue to wonder whether a larger transaction might ultimately occur." ....Sales of the antipsychotic Abilify will start to tumble in 2014, eliminating about $3 billion in revenue by 2016. Even if all the drugs being developed at <span class="company">Bristol Myers</span> make it to market as planned, sales in 2016 will fall about $3.9 billion lower than in 2011, Fernandez said. Andreotti said he plans to make more acquisitions in the near term to help address those losses, and has $10 billion in cash to do so with.<span class="sent"> "Like other drug companies, <span class="company">Bristol Myers</span> may also acquire its way to its stated financial targets if needed," sai Tweet this 

No drug maker faces a bigger threat from generics than Bristol Myers, which will lose products accounting for 60 percent of its 2011 to 2015 earnings, according to Cowen & Co in Boston. Copies of Plavix and the blood pressure medicine Avapro are set to flood the market in 2012, erasing $7.4 billion in sales, said Seamus Fernandez, an analyst in Boston for Leerink Swann & Co. Sales of the antipsychotic Abilify will start to tumble in 2014, eliminating about $3 billion in revenue by 2016. Even if all the drugs being developed at Bristol Myers make it to market as planned, sales in 2016 will fall about $3.9 billion lower than in 2011, Fernandez said 
Share:  No drug maker faces a bigger threat from generics than <span class="company">Bristol Myers</span>, which will lose products accounting for 60 percent of its 2011 to 2015 earnings, according to Cowen & Co in Boston.<span class="sent"> Copies of Plavix and the blood pressure medicine Avapro are set to flood the market in 2012, erasing $7.4 billion in sales, said <span class="analyst">Seamus Fernandez</span>, an analyst in Boston for Leerink Swann & Co.</span> Sales of the antipsychotic Abilify will start to tumble in 2014, eliminating about $3 billion in revenue by 2016. Even if all the drugs being developed at <span class="company">Bristol Myers</span> make it to market as planned, sales in 2016 will fall about $3.9 billion lower than in 2011, Fernandez said....No drug maker faces a bigger threat from generics than <span class="company">Bristol Myers</span>, which will lose products accounting for 60 percent of its 2011 to 2015 earnings, according to Cowen & Co in Boston.<span class="sent"> Copies of Plavix and the blood pressure medicine Avapro are set to flood the market in 2012, erasing $7.4 billion in sales, said <span class="analyst">Seamus Fernandez</span>, an analyst in Boston for Leerink Swann & Co.</span> Sales of the antipsychotic Abilify will start to tumble in 2014, eliminating about $3 billion in revenue by 2016. Even if all the drugs being developed at <span class="company">Bristol Myers</span> make it to market as planned, sales in 2016 will fall about $3.9 billion lower than in 2011, Fernandez said. Tweet this 

Morgan Stanley upgrades Bristol Myers Squibb (NYSE: BMY ) from Equalweight to Overweight. 
Share:  <span class="sent"><span class="analyst">Morgan Stanley</span> upgrades <span class="company">Bristol Myers Squibb</span> (NYSE: BMY ) from Equalweight to Overweight.</span> Tweet this 

Bristol Myers Squibb Co said it plans to introduce five new drugs, including treatments for cancer, diabetes and heart disease, by 2012, as its top selling medicine, the blood thinner Plavix, loses patent protection. The company also said today in a statement that earnings, excluding some costs, will drop to as low as $1.95 a share in 2013 from projected 2010 profit, topping the average estimate of analyst by 7 cents. The five new drugs may generate more than $4 billion by 2016, according Seamus Fernandez, an analyst with Leerink Swann & Co. Bristol Myers is meeting with investors today in New York to detail its plan to overcome the loss of as much as $11 billion in annual sales to generic competition over the next six years. Lamberto Andreotti, 59, named to replace Chief Executive Officer James Cornelius in May, said he will make acquisitions and has as much as $10 billion to spend 
Share:  <span class="company">Bristol Myers Squibb</span> Co said it plans to introduce five new drugs, including treatments for cancer, diabetes and heart disease, by 2012, as its top selling medicine, the blood thinner Plavix, loses patent protection. The company also said today in a statement that earnings, excluding some costs, will drop to as low as $1.95 a share in 2013 from projected 2010 profit, topping the average estimate of analyst by 7 cents.<span class="sent"> The five new drugs may generate more than $4 billion by 2016, according <span class="analyst">Seamus Fernandez</span>, an analyst with Leerink Swann & Co. Bristol Myers is meeting with investors today in New York to detail its plan to overcome the loss of as much as $11 billion in annual sales to generic competition over the next six years.</span> Lamberto Andreotti, 59, named to replace Chief Executive Officer James Cornelius in May, said he will make acquisitions and has as much as $10 billion to spend....<span class="company">Bristol Myers Squibb</span> Co said it plans to introduce five new drugs, including treatments for cancer, diabetes and heart disease, by 2012, as its top selling medicine, the blood thinner Plavix, loses patent protection. The company also said today in a statement that earnings, excluding some costs, will drop to as low as $1.95 a share in 2013 from projected 2010 profit, topping the average estimate of analyst by 7 cents.<span class="sent"> The five new drugs may Tweet this